Updated information on COVID-19 and Flu: Restricted visitation is now in effect
Category
Cancer
Sub Category
Lung
Study Name
EA5163: INSIGNA: A Randomized Phase III Study of First-line Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Post-progression in Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC) with Immuno-biomarker SIGNature-driven Analysis
Principal Investigator
Gordan Srkalovic
Study Information
https://clinicaltrials.gov/ct2/show/NCT03793179
Contact for Questions
Clinical Trials Office – 517.364.9400

Site view: at a glance